Searched for
SOVALDI MEDICINES
Gilead Sciences withdraws writ petition in support of consolidating hearings over patent rightsLegal experts questioned Gilead's decision to take up the matter at the Delhi HC, saying it ought to have directly approached the Kolkata P...- Government's patent grant to Gilead challenged in Delhi High CourtGilead has claimed existing public knowledge as its own and its patent on sofosbuvir, the base compound in its HepC drug Sovaldi, is "unmer...
- Patent not to affect hepatitis C drug price in India: Gilead Sciences Inc"It is the company's goal to enable access to these medicines for as many people as possible, as quickly as possible," the spokesperson add...
- Gilead’s $1,000 pill gets patent in IndiaGilead's patent application was first rejected - just before President Obama's visit in 2015 January - which was seen to be upsetting the U...
- Blockbuster Hepatitis C drug now under price controlDrug-pricing watchdog National Pharmaceutical Pricing Authority (NPPA) has brought under price control revolutionary drug 'Sofosbuvir' pres...
- Americans want to pop made in India Sovaldi drug for 1 per cent of the costThe drug is showing up for sale alongside illegal goods and narcotics on the dark web, which can be accessed through identity-hiding softwa...
- Mylan launches hepatitis-C Sovaldi tablets in IndiaSovaldi is sold by Mylan's dedicated sales force as part of its Hepato Care segment.
- Dr Reddy's shares up on Hepatitis C drug launch planShares of Dr Reddy's Laboratories today settled with gains of nearly 2 per cent after the firm said it is planning to launch Hepatitis C dr...
- Dr Reddy's to launch Hepatitis C drug in IndiaSofosbuvir is a medicine used for chronic Hepatitis C infection and sold globally by Gilead Sciences Inc, under its brand Sovaldi.
- Zydus Cadila launches Gilead's Hepatitis C drug in IndiaSofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences Inc, under its brand Sovaldi.
- Natco Pharma shares soar 15 per centAfter surging 19 per cent to its 52-week high at Rs 2,132.60 in intra-day trade, shares of Natco closed at Rs 2,056.85, up by 14.78 per cen...
- Natco Pharma gets nod to sell Hepatitis C medicine in IndiaThe company has received approval for generic sofosbuvir tablets in the strength of 400 mg from Drugs Controller General (India).
- Natco Pharma ties up with Gilead Sciences for Hepatitis C drugNatco was the only Indian generic drug maker that had filed a pre-grant patent opposition for the drug with the patent office.
- Government may negotiate price of patented drugs before market entryThe government may negotiate prices of patented medicines with their manufacturers before allowing pharmaceutical companies to launch them ...
- Gilead to challenge hepatitis C drug patent rejection decision"The main patent applications covering sofosbuvir are still pending before the Indian Patent Office," Alton said.
- India’s refuses patent to Gilead for its drug SovaldiThe decision of the patent office comes at a time when India-US trade relations are seeing an uptick ahead of President Barack Obama’s visi...
- India warns Egypt companies against selling Sovaldi medicinesIt may also to be mentioned that their production of Sovaldi medicines is still in the R&D stages and have not gone into production yet.
- Hepatitis C medicine being imported for Rs 1 croreThe imported drug comes at around Rs 15 lakh a month, taking the cost to Rs 45-50 lakh for a three-month course.
- National Pharmaceutical Pricing Authority cuts prices of diabetes & heart-disease drugsThe biggest debate on price cuts is happening in the US with patients, insurers and the government joining in.
- Drug price cut of vital medicines a global phenomenonDrug companies say that they are not objecting to the control of healthcare costs, but it is the high-handed approach that is harming the i...
Load More
